GI Colorectal / Rectal Cancer (CRC)

Localized

Colon

Adjuvant

No Trials Currently Available

Anal (Squamous Cell)

Neoadjuvant / Adjuvant

Rectal

Neoadjuvant / Adjuvant

Non-Intervention CRC

IRB# 21658
New study to be available soon.

IRB# 22465
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

IRB# 19296
A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer

IRB# 20980
New study to be available soon.

IRB# 20408
A Phase 1a/b Dose Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signal in Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

IRB# 20408
A Phase 1a/b Dose Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signal in Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

IRB# 20747
A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

IRB# 21972
New study to be available soon.

IRB# 21972
New study to be available soon.

IRB# 20075
[NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

1st Line

Metastatic Anal

IRB# 19576
Phase 1B Study to Assess the Safety of Neoadjuvant TAS-102 (Lonsurf) with Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer

IRB# 20408
A Phase 1a/b Dose Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signal in Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

IRB# 20075
[NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

2nd Line

Metastatic CRC

Beyond 3rd Line

HER2+

Anal (Squamous Cell)

Neoadjuvant / Adjuvant

IRB# 19296
A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer

IRB# 20075
[NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

IRB# 20980
New study to be available soon.

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment
In Development
Enrollment on Hold